Compare Novo Nordisk A/S (NVO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Paychex, Inc. — how do they compare? Novo Nordisk A/S trades at $46.18 (market cap $207.85B), while Paychex, Inc. trades at $120.07 (market cap $43.14B). The key difference: Novo Nordisk A/S is far larger — about 4.8× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| NVO | PAYX | |
|---|---|---|
Market Cap | $207.85B | $43.14B |
Sector | Health | Industrials |
52-Week High | $63.98 | $140.81 |
52-Week Low | $35.29 | $85.57 |
Enterprise Value | $222.55B | $46.63B |
Dividend Yield | 3.81% | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Paychex (PAYX) trades at $121.18, up 0.95% with a bullish technical outlook and strong fundamentals. The company maintains robust profitability with 27.03% net margins and consistent earnings beats. Recent expansion of WISE platform and steady small business employment trends support growth. Technical indicators show bullish momentum with support at $120 and resistance at $122.
PAYX offers stable dividend income and consistent execution but faces valuation concerns with P/E of 24.81 above sector averages. Analyst consensus remains cautious with 63% hold ratings. Key risks include economic sensitivity and competitive pressures in HR services. Upside depends on continued market share gains and margin maintenance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
